Antiretroviral therapy in adults.

In 1993, HIV became the leading cause of death among persons 25 to 44 years old (Centers for Disease Control and Prevention [CDC], 1995a). As the number of cases has increased, the disease has moved increasingly into minority populations, who, traditionally, have fewer financial resources. Rates of HIV infection among women, Blacks, and Hispanics have increased steadily since 1985. The incidence of AIDS has been higher among Black and Hispanic men than among White men (CDC, 1995b). In 1994, the rates for Black and Hispanic women were 16 and 7 times higher, respectively, than the rate for White women, with Black and Hispanic women accounting for 77% of the cases among women (CDC, 1995b, c). The U.S. health care system, already inadequate in addressing the needs of the medically indigent, is likely to become increasingly overwhelmed with the care of HIV-positive individuals. It is probable that nurse practitioners will play a key role in providing primary care for HlV. As a result, a thorough understanding of antiretroviral therapy will be critical to competent patient management.

[1]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[2]  J. Nielsen,et al.  Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. , 1994, JAMA.

[3]  M. Uhlén,et al.  Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. , 1994, The Journal of infectious diseases.

[4]  W. Freimuth Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. , 1996, Advances in experimental medicine and biology.

[5]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[6]  M. Hirsch,et al.  Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.

[7]  P. Furth,et al.  Nail pigmentation changes associated with azidothymidine (zidovudine). , 1987, Annals of internal medicine.

[8]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[9]  D. Cooper,et al.  Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia , 1990 .

[10]  D. Jeffries,et al.  Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. , 1989, The Journal of infection.

[11]  A. Lazzarin,et al.  Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV‐related thrombocytopenia , 1993, AIDS.

[12]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[13]  M. Wulfsohn,et al.  A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome , 1990 .

[14]  J. Cohen,et al.  Acetaminophen does not impair clearance of zidovudine. , 1991, Annals of internal medicine.

[15]  B. Larder,et al.  Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates , 1993, Antimicrobial Agents and Chemotherapy.

[16]  B. Efron,et al.  Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy , 1994, Annals of Internal Medicine.

[17]  J. Lange,et al.  Treatment of HIV Infection , 1996, Drug safety.

[18]  D. Richman,et al.  A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.

[19]  J. Montaner,et al.  A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.

[20]  J. Phair,et al.  The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. , 1994, JAMA.

[21]  J. Barrish,et al.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.

[22]  O. Paltiel,et al.  Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virus , 1995, American journal of hematology.

[23]  J. Veenstra,et al.  The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. , 1995, The Journal of infectious diseases.

[24]  D. McCluskey The medical management of AIDS , 1989, The Lancet.

[25]  Robert T. Schooley,et al.  Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex , 1989 .

[26]  J. Fitzgibbon,et al.  Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. , 1993, The New England journal of medicine.

[27]  R. Schooley,et al.  Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. , 1989, JAMA.

[28]  D. Kuritzkes,et al.  Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .

[29]  M. Falguera,et al.  Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine , 1995, European journal of haematology.

[30]  J. Sommadossi Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues. , 1995, The Journal of infectious diseases.

[31]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[32]  Anne M Johnson,et al.  Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine , 1994 .

[33]  J. Gatell,et al.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter , 1993 .

[34]  P. Klenerman,et al.  Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. , 1994, The Journal of infectious diseases.

[35]  T. Poynard,et al.  Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients , 1995, The Lancet.

[36]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[37]  V. Herbert,et al.  Synergy of inhibition of DNA synthesis in human bone marrow by azidothymidine plus deficiency of folate and/or vitamin B12? , 1990, American journal of hematology.

[38]  S. Larson,et al.  Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease , 1988, Annals of neurology.

[39]  B. Gazzard,et al.  Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients. , 1993, AIDS.

[40]  D. Katzenstein,et al.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.

[41]  W. Guerra Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .

[42]  M. Fischl,et al.  Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy , 1993, Annals of Internal Medicine.

[43]  J. Phair,et al.  A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[44]  T. Merigan,et al.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[45]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[46]  J. Phair,et al.  Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). , 1994, Journal of acquired immune deficiency syndromes.

[47]  Update: acquired immunodeficiency syndrome--United States. , 1986, MMWR. Morbidity and mortality weekly report.

[48]  M. Saag,et al.  Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? , 1994, Infectious agents and disease.

[49]  Paul Kellam,et al.  Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.

[50]  H. Burger,et al.  Safety and activity of saquinavir in HIV infection , 1995, The Lancet.

[51]  P Bacchetti,et al.  Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. , 1991, BMJ.

[52]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[53]  M. Dudley Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.

[54]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[55]  J. Sninsky,et al.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.

[56]  S. Safrin,et al.  Drug interactions and toxicities in patients with AIDS , 1992 .

[57]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[58]  A. James Fat-soluble vitamins , 1995, The Lancet.

[59]  E. Clercq New Developments in the Chemotherapy of Lentivirus (Human Immunodeficiency Virus) Infections: Sensitivity/Resistance of HIV‐1 to Non‐nucleoside HIV‐1‐specific Inhibitors a , 1994 .

[60]  G L Drusano,et al.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. , 1992, The New England journal of medicine.

[61]  S. Hammer,et al.  Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.

[62]  T Creagh-Kirk,et al.  Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. , 1988, JAMA.

[63]  Douglas D. Richman,et al.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial , 1990 .

[64]  P. Volberding,et al.  Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. , 1994, The New England journal of medicine.

[65]  C. Hendrix,et al.  PROBENECID AND ZIDOVUDINE METABOLISM , 1989, The Lancet.

[66]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[67]  J. Phair,et al.  CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. , 1993, Journal of acquired immune deficiency syndromes.

[68]  A. Cross,et al.  Dose-related activity of stavudine in patients infected with human immunodeficiency virus. , 1995, The Journal of infectious diseases.

[69]  Update: AIDS among women--United States, 1994. , 1995, MMWR. Morbidity and mortality weekly report.